akina pharmacy tirzepatide / Niacinamide Injection akina pharmacy semaglutide Medical Weight

Understanding outcomes in this phase helps set realistic expectations for both patients and clinicians

Courville, C

Zepbound is FDA-approved for two indications: chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with a weight-related condition (November 2023), and obstructive sleep apnea in adults with obesity (December 2024, based on SURMOUNT-OSA)

Regardless of their effects on gut microflora, these studies confirm that PGN can induce GI lesions, while CGN does not

So for now at least, the researchers are still advising that people with a personal or family history of MTC (or a closely related, inherited condition called MEN2) not take these drugs